RHO CAPITAL PARTNERS INC
Follow13F filer, CIK 1020455, NEW YORK, NY
RHO CAPITAL PARTNERS INC reported $144,552,000 across 5 holdings for the quarter ended 2022-03-31, in a 13F-HR filed 2022-05-11.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001420506-22-000785
- Period
- 2022-03-31
- Reported value
- $145M
- Holdings
- 5
- Top 10 weight
- 100%
- New
- 0
- Sold out
- 0
Holdings, Q1 2022
Share positions as resolved from 13F-HR 0001420506-22-000785, largest first. % of portfolio is the value over $144,552,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| CHARGEPOINT HLDGS INCCHARGEPOINT HLDGS INC | 4,053,257 | $80.6M | 55.74% | 0 | |||
| NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INC | 3,766,666 | $57.4M | 39.74% | 0 | |||
| Mersana Therapeutics IncMersana Therapeutics Inc | 796,458 | $3.18M | 2.2% | 0 | |||
| LIVEONE INCLIVEONE INC | 3,724,137 | $3.04M | 2.1% | 0 | |||
| SENSEONICS HLDGS INCSENSEONICS HLDGS INC | 159,601 | $314K | 0.22% | 0 |
How Q1 2022 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001420506-22-000785 | base | 2022-05-11 | acceptance time not in the bulk data set |